ArticleDigestive diseases and sciences2026
Effect of 5-Aminosalicylate Dose Reduction or Withdrawal on Prognosis in Patients with Ulcerative Colitis Receiving Advanced Therapy: A Multicenter Retrospective Cohort Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe role of 5-aminosalicylates (5-ASA) in maintaining remission in patients with ulcerative colitis (UC) receiving advanced therapy remains controversial. This study evaluated the safety and feasibility of 5-ASA discontinuation and dose reduction in patients with UC who achieved remission with advanced therapies.
methodsThis multicenter retrospective cohort study included patients with UC who achieved steroid-free clinical remission with advanced therapies at three centers (2010-2025). Patients were categorized into continuation or discontinuation groups based on 5-ASA status after achieving remission. The primary outcome was time to clinical relapse. Dose reduction versus dose maintenance was also evaluated among patients who continued 5-ASA.
results170 treatment episodes were analyzed: 153 in the continuation group and 17 in the discontinuation group. The relapse rate was 17.6% (3/17) in the discontinuation group and 18.3% (28/153) in the continuation group, with no significant difference in relapse-free survival (log-rank P = 0.597). Among continuers, 21 underwent dose reduction and 132 maintained their dose; dose reduction did not increase relapse risk (log-rank P = 0.273). Cox regression analysis showed 5-ASA discontinuation was not associated with increased relapse risk (HR: 0.719, 95% CI: 0.218-2.378, P = 0.589), with only prior advanced therapy exposure significantly predicting relapse.
conclusionThis is the first real-world study evaluating 5-ASA discontinuation in patients with UC achieving remission with advanced therapies. Discontinuation or dose reduction of 5-ASA might not be associated with increased relapse risk in carefully selected patients. Although limited sample size restricts definitive conclusions, these findings suggest reducing medication burden may be feasible in selected patients.
Indexed as
Identifiers
41770422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.